Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15217604 | 0.82 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1LMNAPRMT5WDR77 | |
| SCHEMBL23914629 | 0.77 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1LMNAPRMT5WDR77 | |
| SCHEMBL15217609 | 0.74 | SMN1; SMN2 (0.45) | SMN1; SMN2ALDH1A1LMNAPRMT5WDR77 | |
| SCHEMBL9377801 | 0.74 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1LMNAHPGDPOLB | |
| SCHEMBL15217619 | 0.74 | SMN1; SMN2 (0.42) | SMN1; SMN2ALDH1A1LMNAPRMT5WDR77 | |
| SCHEMBL23915506 | 0.74 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1LMNAHPGDMAPT | |
| SCHEMBL9378653 | 0.74 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1LMNAHPGDPARP1 | |
| SCHEMBL15217622 | 0.74 | SMN1; SMN2 (0.45) | SMN1; SMN2ALDH1A1LMNAPRMT5WDR77 | |
| SCHEMBL15217613 | 0.74 | SMN1; SMN2 (0.45) | SMN1; SMN2ALDH1A1LMNAPRMT5WDR77 | |
| SCHEMBL361109 | 0.74 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1LMNAPRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163073-A1 | ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2025-05-22 | — | — | US | disclosed |
| US-12077547-B2 | Aldose reductase inhibitors and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-09-03 | — | — | US | disclosed |
| EP-4316603-A2 | 4-OXO-3,4-DIHYDROTHIENO[3,4-D]PYRIDAZINE COMPOUNDS AS ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | The Trustees of Columbia University in the City of New York (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-3757107-B1 | 4-OXO-3,4-DIHYDROTHIENO[3,4-D]PYRIDAZINE COMPOUNDS AS ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | UNIV COLUMBIA (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230312599-A1 | ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-10-05 | — | — | US | disclosed |
| US-20230312599-A1 | ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-10-05 | — | — | US | disclosed |
| US-11498925-B2 | Aldose reductase inhibitors and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-11-15 | — | — | US | disclosed |
| CN-115160339-A | Aldose reductase inhibitors and methods of use thereof | 纽约市哥伦比亚大学理事会 | 2022-10-11 | — | — | CN | disclosed |
| CN-109310674-B | Aldose reductase inhibitors and methods of use thereof | 纽约市哥伦比亚大学理事会 | 2022-07-08 | — | — | CN | disclosed |
| US-20210284652-A1 | ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2021-09-16 | — | — | US | disclosed |
| EP-3757107-A1 | 4-OXO-3,4-DIHYDROTHIENO[3,4-D]PYRIDAZINE COMPOUNDS AS ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | The Trustees of Columbia University in the City of New York (US) | 2020-12-30 | — | — | EP | disclosed |
| US-10870658-B2 | Aldose reductase inhibitors and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-12-22 | — | — | US | disclosed |
| US-20200283451-A1 | ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2020-09-10 | — | — | US | disclosed |
| EP-3352754-B1 | ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | UNIV COLUMBIA (US) | 2020-09-02 | — | — | EP | disclosed |
| US-10647726-B2 | Aldose reductase inhibitors and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190300543-A1 | ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2019-10-03 | — | — | US | disclosed |
| US-10150779-B2 | Aldose reductase inhibitors and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-12-11 | — | — | US | disclosed |
| US-20180237451-A1 | ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2018-08-23 | — | — | US | disclosed |
| EP-3352754-A1 | ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | The Trustees of Columbia University in the City of New York (US) | 2018-08-01 | — | — | EP | disclosed |
| WO-2017223179-A1 | ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163073-A1 | ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | ALDOA, AKR1B1, AKR1C2 | SMN1; SMN2 1667/4885ALDH1A1 23/4885LMNA 1364/4885 |
| US-10870658-B2 | Aldose reductase inhibitors and methods of use thereof | ALDOA, AKR1B1, AKR1C2 | SMN1; SMN2 1667/4885ALDH1A1 23/4885LMNA 1364/4885 |
| US-11498925-B2 | Aldose reductase inhibitors and methods of use thereof | ALDOA, AKR1B1, AKR1C2 | SMN1; SMN2 1667/4885ALDH1A1 23/4885LMNA 1364/4885 |
| US-20200283451-A1 | ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | ALDOA, AKR1B1, AKR1C2 | SMN1; SMN2 1667/4885ALDH1A1 23/4885LMNA 1364/4885 |
| US-20210284652-A1 | ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | ALDOA, AKR1B1, AKR1C2 | SMN1; SMN2 1667/4885ALDH1A1 23/4885LMNA 1364/4885 |
| US-20180237451-A1 | ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | ALDOA, AKR1B1, AKR1C2 | SMN1; SMN2 1667/4885ALDH1A1 23/4885LMNA 1364/4885 |
| US-20190300543-A1 | ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | ALDOA, AKR1B1, AKR1C2 | SMN1; SMN2 1667/4885ALDH1A1 23/4885LMNA 1364/4885 |
| US-20230312599-A1 | ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | ALDOA, AKR1B1, AKR1C2 | SMN1; SMN2 1667/4885ALDH1A1 23/4885LMNA 1364/4885 |
| US-10150779-B2 | Aldose reductase inhibitors and methods of use thereof | ALDOA, AKR1B1, AKR1C2 | SMN1; SMN2 1667/4885ALDH1A1 23/4885LMNA 1364/4885 |
| US-10647726-B2 | Aldose reductase inhibitors and methods of use thereof | ALDOA, AKR1B1, AKR1C2 | SMN1; SMN2 1667/4885ALDH1A1 23/4885LMNA 1364/4885 |
| US-12077547-B2 | Aldose reductase inhibitors and methods of use thereof | ALDOA, AKR1B1, AKR1C2 | SMN1; SMN2 1667/4885ALDH1A1 23/4885LMNA 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.